Skip to main content
Full access
Letters
Published Online: 1 January 2014

Successful Treatment of Catatonia in a Young Man With Schizophrenia and Progressive Diffuse Cerebral Atrophy

Publication: The Journal of Neuropsychiatry and Clinical Neurosciences
To the Editor: This report describes the case of a young man with schizophrenia, catatonic type, and progressive brain volume loss on MRI who responded well to aggressive treatment of catatonic symptoms.

Case Report

“Mr. A.” is an 18-year-old White man who was diagnosed with schizophrenia at age 16. Before the onset of his first psychiatric symptoms, he had done very well in school. At age 16, the family began to notice unusual behavior: gradually withdrawing from interactions with family and friends; talking less; staring; refusing to go school; standing up for hours at the bus station.
Mr. A. was diagnosed with schizophrenia and subsequently had trials of various psychotropic medications without significant improvement, partly due to medication nonadherence. When the situation became unmanageable because of A’s escalating aggressive behavior, he required hospitalization at our state facility.
At the beginning of this hospitalization, Mr. A. presented as being selectively mute, staring, posturing, striking out at staff, and not attending to his personal hygiene. A trial of lorazepam (up to 6 mg po/day) and clozapine temporarily improved his aggressive behavior.
An MRI of his brain showed mild-to-moderate diffuse volume loss greater than expected for the patient’s age and progressive when compared with an MRI of the brain done at age 16. Mr. A. was diagnosed with Dementia, NOS. A medication washout and re-evaluation was done. His clinical status severely deteriorated. He was spending most of the time lying in bed in a fixed position, with staring and posturing, and at times showing aggressive behavior.
A consulting neurologist ruled out metachromatic leukodystrophy, systemic lupus erythematosus, Sjogren’s disease, Hashimoto’s thyroiditis, Wilson’s disease, velocardiofacial syndrome, Tay-Sachs disease, Sandhoff disease, HIV, and amino acids defects.
After he was transferred to our ward, Mr. A. was aggressively treated for catatonia. He responded well to a combination of clozapine, a high dose of lorazepam (12–14 mg po and im/day), divalproex, and amantadine. Maximal response was noted after 8 weeks of treatment. Trials of memantine and topiramate were unsuccessful, suppressing his appetite and leading to no greater improvement. Over the ensuing 4 weeks, he continued to improve in all areas of functioning by becoming independent with his ADLs. His speech was logical and coherent.

Discussion

Was the initial presentation at age 16 consistent with catatonia? Is catatonia in this case a different disorder from schizophrenia, catatonic type?1 If this is schizophrenia, catatonic type, and the onset was typical for schizophrenia, is catatonia the end result of a progressively deteriorating course in the absence of consistent treatment with psychotropic medications? Is there a parallel between the progressive cerebral atrophy and the worsening of catatonia?
This case is illustrative of the response of catatonia to certain psychotropic medications previously reported in the literature, such as high doses of benzodiazepines,2 clozapine,3 divalproex, and, to a lesser degree in this case, amantadine.4 It is unclear whether amantadine played a significant role in this patient’s improvement, as the response to this medication was not spectacular, although significant muscle relaxation was noted after the first dose. The responses to memantine4 and topiramate4,5 were minimal; when benefits were weighed against side effects, the severe suppressant effect on appetite required discontinuation of these two medications.

References

1.
Fink M, Shorter E, Taylor MA: Catatonia is not schizophrenia: Kraepelin’s error and the need to recognize catatonia as an independent syndrome in medical nomenclature. Schizophr Bull 2010; 36:314–320
2.
Daniels J: Catatonia: clinical aspects and neurobiological correlates. J Neuropsychiatry Clin Neurosci 2009; 21:371–380
3.
England ML, Ongür D, Konopaske GT, et al.: Catatonia in psychotic patients: clinical features and treatment response. J Neuropsychiatry Clin Neurosci 2011; 23:223–226
4.
Carroll BT, Goforth HW, Thomas C, et al.: Review of adjunctive glutamate antagonist therapy in the treatment of catatonic syndromes. J Neuropsychiatry Clin Neurosci 2007; 19:406–412
5.
McDaniel WW, David R: Spiegel at al: Topiramate effect in catatonia. J Neuropsychiatry Clin Neurosci 2006; 18:234–238

Information & Authors

Information

Published In

Go to The Journal of Neuropsychiatry and Clinical Neurosciences
Go to The Journal of Neuropsychiatry and Clinical Neurosciences
The Journal of Neuropsychiatry and Clinical Neurosciences
Pages: E21 - E22
PubMed: 24515696

History

Published online: 1 January 2014
Published in print: Winter 2014

Authors

Details

Valerica Ene-Stroescu, M.D.
Department of Psychiatry Western State Hospital, Tacoma WA
Thanh Nguyen, M.D.
Department of Psychiatry Western State Hospital, Tacoma WA
Brian E. Waiblinger, M.D.
Department of Psychiatry Western State Hospital, Tacoma WA

Notes

Correspondence: Valerica Ene-Stroescu, M.D. e-mail [email protected]

Competing Interests

The authors indicate that they have no conflict of interest to disclose and no support was received from any grant or other funding source.

Metrics & Citations

Metrics

Citations

Export Citations

If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.

For more information or tips please see 'Downloading to a citation manager' in the Help menu.

Format
Citation style
Style
Copy to clipboard

View Options

View options

PDF/EPUB

View PDF/EPUB

Login options

Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.

Personal login Institutional Login Open Athens login
Purchase Options

Purchase this article to access the full text.

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

PPV Articles - Journal of Neuropsychiatry and Clinical Neurosciences

Not a subscriber?

Subscribe Now / Learn More

PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

Media

Figures

Other

Tables

Share

Share

Share article link

Share